Whats new
Analyst reports.
This information is provided for information purposes only. The opinions, estimates, forecasts or any analysis do not represent the opinions, forecasts, or any analysis of our Company or management or staff. We do not by its reference imply any concurrence with the independently provided opinions, estimates or forecasts.
Analyst Reports
Analyst Reports
March 5th 2021
Bell Potter - Stage 2 of 2nd line NSCLC patient cohort in Phase 2 TACTI-002 trial starts recruitment (Analyst: Tanushree Jain)
February 25th 2021
Bell Potter - 1H21 Results broadly in-line (Analyst: Tanushree Jain)
February 5th 2021
Bell Potter - Strong balance sheet with several catalysts (Analyst: Tanushree Jain)
October 27th 2020
Bell Potter - Efti now tackling COVID-19 (Analyst: Tanushree Jain)
September 17th 2020
Bell Potter - Underappreciated immunotherapy player with leadership in LAG-3 (Analyst: Tanushree Jain)
June 3rd 2020
Bell Potter - ASCO data further builds case for efti+Keytruda, with HNSCC looking more attractive (Analyst: Tanushree Jain)
March 27th 2020
Bell Potter - Phase 2b AIPAC trial results provide path forward in metastatic breast cancer (Analyst: Tanushree Jain tnjain@bellpotter.com.au)
February 18th 2020